Stereotaxis, Inc. · AMEX:STXS
Stereotaxis — Investor Presentation
17 slides from Stereotaxis's investor presentation
Slide 1: Investor Presentation 3Q 2026
INVESTOR PRESENTATION 3Q 2026
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS During the course of this presentation, the Company may make projections and other forward- looking statements regarding future events or the future financial performance of the Company, including without limitation, statements regarding future operating results, growth op
Slide 3: Pioneering Endovascular Surgical Robotics
Pioneering ENDOVASCULAR SURGICAL ROBOTICS Highly Leadership Global Robust Solid Differentiated In Large Commercial Clinical Financial Technology Markets Presence Value Foundation Unique robotic solutions Only robotic technology in $16B+ 150,000+ patients treated 500+ publications $10M+ cash & no deb
Slide 4: Robotics Transforming Surgery
ROBOTICS TRANSFORMING SURGERY Open Surgery Laparoscopic Surgery Endovascular Interventions >5,000 Installed Robots >10,000 Installed Robots >500,000 Robotic Procedures/Year >3,000,000 Robotic Procedures/Year \ 4
Slide 5: Why Has Endovascular Robotics Lagged?
Why Has Endovascular Robotics Lagged? 1 . Challenging Anatomy 2 . Challenging Devices Small, Delicate, Tortuous Anatomy Catheters are Flexible Instruments 5
Slide 6: Transforming Catheter Navigation
TRANSFORMING CATHETER NAVIGATION ROBOTIC MAGNETIC Traditional Catheters NAVIGATION (RMN) Direct control of the catheter tip using Catheter controlled from the handle precise magnetic fields several feet from the patient's heart Precision Limited Precision, Stability & Reach 1 . Moving the tip of a m
Slide 7: Robotic Magnetic Navigation (RMN)
ROBOTIC MAGNETIC NAVIGATION (RMN) Robotic Magnetic Navigation System External computer-controlled permanent magnets create a magnetic field within which a catheter with a magnetic tip can be precisely maneuvered. Physician Cockpit Physician sits at a computer control station, views procedure data on
Slide 8: Meaningful Clinical Impact & Real-World Validation
MEANINGFUL CLINICAL IMPACT & REAL-WORLD VALIDATION Global Broad Attractive Robot Adoption Patient Care Clinical Data >100 Hospitals >150,000 Patients >500 Publications 8
Slide 9: Patient Safety & Outcomes
PATIENT SAFETY & OUTCOMES 72% Fewer Major Complications 6-8% Improved ST & LT Efficacy 36% Less Radiation Exposure *Data on file with Stereotaxis and available at RoboticEP.com; from review of clinical literature comparing robotic to manual cardiac ablation Enabling Advanced Patient Care “For ventri
Slide 10: Physician Safety & Experience
PHYSICIAN SAFETY & EXPERIENCE OCCUPATIONAL HAZARDS ENHANCED EXPERIENCE Risks of the Manual Cath Lab: Benefits of Robotic Cath Lab: 85% 49% Left vs Right Sided Orthopedic Injury Brain Tumors Cognitive Skill Elevated Full Control Democratization of Skill Enhanced environment and Control over the entir
Slide 11: Key Strategic Transformations
KEY STRATEGIC TRANSFORMATIONS Robotic Lab Constraints High cost and burden to adopt a robot, Accessible Robot including architectural planning, lab Easily Accessible Without Construction construction and an integrated x-ray. Catheter Dependency Dependency on J&J for ablation catheter Razorblade Mode
Slide 12: Strategic Transformation at Inflection Point
STRATEGIC TRANSFORMATION AT INFLECTION POINT GenesisX: Initiating Commercialization Following FDA Clearance & CE Mark Accessible Robot • • Shift from construction process to weekend install (no room shielding; simple power; smaller; lighter; reversible) Shortens sales cycle and increases opportunity
Slide 13: Innovation Driving Growth
INNOVATION DRIVING GROWTH AI Primary Revenue Synchrony AI Growth Drivers: Robocath Increased System Sales with Accessible Robot Shift from construction process to mobile robot with rapid installation IC/NI GenesisX IC/NI Increased EP Catheter Revenue IC/NI Shift from a single disposable to a portfol
Slide 14: Four Commercial Opportunities
FOUR COMMERCIAL OPPORTUNITIES Electrophysiology Interventional Neurointervention Cath Labs Cardiology $15B+ $20B+ $5B $1B TAM TAM TAM TAM 8,000+ EP Labs Performing 5M+ PCI Procedures Cardiac Ablation Annually 1M Neuro Procedures 20,000+ Cath Labs - - Annually Globally 2M Cardiac Ablation 2M+ Periphe
Slide 15: Tech Leadership & Innovation Pipeline
TECH LEADERSHIP & INNOVATION PIPELINE Magnetic Robots Mechanical Robots Advanced Catheters Digital Surgery Fully Mobile, Unobtrusive, Performing the Full Range With a Matching Portfolio of Enhanced with Intelligence, Interoperable, & Accessible Robots of Activities Across EP/IC/NI Advanced Intervent
Slide 16: Governance & Financial Prudence
GOVERNANCE & FINANCIAL PRUDENCE Aligned Capital Robust Clean Board & Leadership Efficient & Prudent Existing Business Balance Sheet Significant Shareholders Low Cash Utilization 2025 Revenue $32M $10M+ Cash Stock Comp Plan at $1-5B MC Significant Operating Leverage Grew 20% YoY No Debt 16
Slide 17: Thank You
THANK YOU Innovative Technology • Highly Differentiated Approach for Endovascular Surgery • Global Leadership in Endovascular Robotics Proven Clinical Value • Enables Therapy and Improves Patient Outcomes • Extensive Real-World Clinical Validation Solid Foundation • Financial Prudence: Clean Balance